Latest News and Press Releases
Want to stay updated on the latest news?
-
Up to a Total of $493 Million in Upfront, Sales and Development Milestone Payments, as well as Royalties on Net Sales KemPharm Will Host a Conference Call and Live Audio Webcast with Slide...
-
CELEBRATION, Fla., Aug. 13, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...
-
Development & Regulatory Highlights: Completed KP415 Pre-NDA Meeting with FDAProvided Update on APADAZ® Formulary AdoptionAnnounced FDA Approval of sNDA for Two Additional Strengths of APADAZ ...
-
KP415 NDA Filing Anticipated in Late Q2 or Early Q3 2019 Conference Call Scheduled for Today, Thursday, April 11, 2019 at 5:00 p.m. ET CELEBRATION, Fla., April 11, 2019 (GLOBE NEWSWIRE) --...
-
Conference Call Scheduled for Today, Wednesday, March 13, 2019 at 8:30 a.m. ET Highlights: According to MMIT estimates, the authorized generic for APADAZ has unrestricted formulary access for 91% of...
-
CELEBRATION, Fla., March 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today...
-
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development & Regulatory Highlights: Completed KP415 clinical and human abuse...
-
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, February 28, 2019, 4:30 p.m. ET CELEBRATION, Fla., Feb. 21, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc....
-
Patents Extend Across KemPharm’s Prodrug Portfolio, Including IP Protection for KP415 in Canada, Japan and Korea CELEBRATION, Fla., Jan. 29, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH),...
-
Posters include intranasal and oral HAP data for serdexmethylphenidate (SDX), as well as PK data for KP415 Intranasal HAP data selected to be presented during oral “data blitz session” ...